Revenue Projections Could Dwarf Britain’s Expected $10 Million per Year Due to Many Times Higher Birth Rates in Latin America
TORONTO, ON–(Marketwired – Aug 4, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces Easton and BMV have signed an agreement and made a payment to Common Sense LTD. of Israel for the exclusive rights to market and sell Common Sense’s AL-Sense (Amniotic-Sense-Blue) Amniotic Fluid Leak Test for most of Latin America.
TORONTO, ON–(Marketwired – Jul 29, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces the appointment of Evan Karras as CEO & Director and announces Mr. Nunzio Valerie as President and Director.
TORONTO, ON–(Marketwired – Jul 6, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces positive update from Ackerman Pharma; where the regulatory filing and anticipated approval process for the cancer drugs Paclitaxel and Docetaxel has been shortened.
TORONTO, ON–(Marketwired – Jun 23, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces that Easton and BMV have decided on Eva Pro as brand name for its line of patented women’s diagnostic tests for Mexico and possibly the Latin American market. The Eva Pro brand will include both the already secured vaginal infection diagnostic test and most likely the amniotic fluid leak test for late pregnancy. Easton / BMV move toward Trademarking and provides update on Latin American market.
The VS-Sense Diagnostic Product Line Currently Holds Extended Patent Protection and Is Expected to Generate Well Over 100% Profit Margins for Easton / BMV; The Vaginal Health Test Is Currently Sold throughout the United States, Canada and Soon Europe.
TORONTO, ON–(Marketwired – Dec 31, 2014) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has signed an agreement with Medicated Markets International LLC., a major California medical marijuana grower.
TORONTO, ON–(Marketwired – Mar 11, 2014) – Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it nearing its limit on financing under regulation offerings.
